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Endothelial-monocyte-activating polypeptide-II (EMAP-II) is a novel multifunctional polypeptide with proinflammatory activity. We
have previously shown that the recombinant and native forms of EMAP-II can induce apoptosis in mitogen-stimulated lymphocytes,
and that the release of this protein into the extracellular milieu is enhanced by hypoxia. We hypothesised that hypoxia may lead to
death of tumour-infiltrating lymphocytes (TILs) via an EMAP-II-dependent mechanism, thereby assisting tumours to evade the
immune system. In this study, we used immunohistochemistry to detect EMAP-II, active caspase-3 and cleaved Poly (ADP-ribose)
Polymerase (PARP) as indicators of apoptosis in TILs, and carbonic anhydrase IX (CA IX) as a surrogate marker of hypoxia. EMAP-II
expression is associated with regions of hypoxia, and furthermore there is a significant association between TILs apoptosis and the
presence of hypoxia. Using a coculture model of colorectal cancer cell/lymphocyte interactions, we were also able to demonstrate
lymphocyte apoptosis induced by tumour cells, with concomitant caspase-3 activity. Lymphocyte killing was enhanced by direct cell–
cell contact, particularly by tumour cells exposed to hypoxic conditions. Our data support the hypothesis that hypoxia plays a role in
immune evasion by tumour cells, through EMAP-II-dependent lymphocyte killing.
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Endothelial-monocyte-activating polypeptide-II (EMAP-II) was
first detected in supernatants of cultured murine tumour cells
(Berger et al, 2000; Murray and Tas, 2001) based on its ability to
stimulate procoagulant activity in cultured endothelial cells. Kao
et al (1992) isolated 20–22kDa EMAP-II protein, which proved to
have pleiotropic, cytokine-like activity towards endothelial cells as
well as monocytes and neutrophils (Kao et al, 1994). EMAP-II is
believed to be synthesised as a 34-kDa precursor molecule, which
is proteolytically cleaved to produce the 20-kDa mature poly-
peptide (Tas et al, 1997). EMAP-II and the p43 auxiliary component
of the mammalian multisynthetase complex share a high degree of
amino-acid identity (Quevillon et al, 1997), although the precise
relationship between these polypeptides is not understood.
It has been suggested that EMAP-II is released from cells as a
consequence of activation of programmed cell death (Knies et al,
1998), and we showed that enhanced processing and release of
mature protein are initiated in response to cellular stress (Barnett
et al, 2000). More recently, we showed that EMAP-II induces
apoptosis in mitogen stimulated lymphocytes, and suggested that
EMAP-II might therefore act in an immuno-suppressive role in the
tumour milieu, protecting tumour cells from activated lympho-
cytes (Murray et al, 2004).
Colorectal cancer (CRC) is characterised by regions of variable
hypoxia (Moulder and Rockwell, 1984). Hypoxic growth can result
in a tumour with more aggressive growth characteristics and more
malignant phenotype (Harris, 2002). Hypoxia-induced apoptosis
of tumour-infiltrating lymphocytes (TILs) might provide another
growth benefit to the tumour, favouring growth of more resistant
tumour cells. In this study, we provide evidence to support the
hypothesis that hypoxia leads to apoptosis of TILs, and that
EMAP-II may play a role in this mechanism, protecting tumour
cells against the immune system.
MATERIALS AND METHODS
Tissue samples
Formalin-fixed, paraffin-embedded archival tissue samples from
72 patients diagnosed with colorectal tumours at the Nottingham
City Hospital between 1991 and 1992 were used in this study. All
tumour samples were coded to conserve patient confidentiality.
The adenomatous lesions included one villous, four tubulo-villous
and six tubular tumours. The study was approved by the Research
Ethics Committee of Nottingham City Hospital.
Cell lines
The human leukemic T-cell line Jurkat, the colorectal adenocarci-
noma cell lines DLD-1 and HT29 were obtained from American
Type Culture Collection (Manassas, VA, USA).
Cell culture and induction of hypoxia in vitro
The cell lines were cultured in RPMI-1640 medium (Life Techno-
logies, Paisley, UK), supplemented with 10% fetal calf serum (PAA
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sLaboratories, Lintz, Austria) and 100Uml
 1 penicillin/strepto-
mycin solution (Sigma-Aldrich, Poole, UK). Cells were maintained
at 371Ci n5 %C O 2 in a humidified incubator and were routinely
subcultured by removal from flasks with 0.05% trypsin/1mM
EDTA (Sigma-Aldrich). For exposure to a hypoxic environment,
subconfluent cells in serum-free medium were incubated in a
hypoxic chamber containing 1% O2,5 %C O 2, and 94% N2 for 4, 16
and 24h and in normal conditions as a control.
Coculture model
The contact and noncontact cocultivations were carried out in 24-
well plates (5mm pore size; Corning Costar, Cambridge, UK). For
noncontact coculture, DLD-1 and HT29 tumour cells were added at
50000cellswell
 1 in the lower chambers. We kept on looking at
the cells to assure that they adhered to the wells. On the day of the
experiment, we treated some cells either by tumour necrosis
factor-a (TNF-a) and interferon-g (IFN-g)2 0 n g m l
 1 to enhance
release of EMAP-II or with TNF-a/IFN-g and rabbit polyclonal
antibodies against human EMAP-II (R2B2) at different concentra-
tions to block endogenous EMAP-II. Purified rabbit IgG (IgG)
antibody (R&D Systems, Abingdon, UK) was used as a negative
control. The Jurkat cells were plated out at. The Jurkat cells
were plated out at 200000cellswell
 1 in the upper chamber in the
presence of phytohaemag-glutinin (PHA) (1mgml
 1). In contact
coculture, there is a coculture in the same well. The culture was
done in normoxia and hypoxia for 4 and 16h, respectively. The
nonadherent Jurkats were removed and centrifuged at 1000 g for
5min. Samples were analysed using active caspase-3, described
below. The samples were done in triplicates.
Caspase-3 activity assay
A commercially available kit was used to detect activated caspase-3
activity in cell lysates (Oncogene, Research Products, Nottingham,
UK), which takes advantage of the specificity of the enzyme for
cleavage after aspartate residues in particular peptide sequence
(DEVD). The DEVD substrate is labelled with a fluorescent
molecule, 7-amino-4-trifluoromethyl coumarin (AFC), and the
reaction is monitored by a blue to green shift in fluorescence upon
cleavage of the AFC fluorophore. Caspase-3 activity was measured
in extracts of control Jurkat T cells, cells from contact or
noncontact cocultures with tumour cells in normoxia and hypoxia
after 4 and 16h, respectively, using a fluorescent plate reader. The
data are expressed as the relative fluorescence intensity (RFU) after
subtraction of the relative signal of the appropriate buffer controls.
RFU represents sample fluorescence/control fluorescence intensity
based on three separate experiments.
Assessment of apoptosis by FITC-labelled annexin-V
iodide
Annexin-V and propidium iodide (PI) reagents can be used together
to distinguish early and late apoptosis (Vermes et al, 1995; Martin
et al, 1995). Jurkat T cells, following coculture with tumour cell
monolayers for 24h under normal and hypoxic conditions, were
assessed for apoptosis. Tumour cells were either untreated
or treated with 20ngml
 1 TNF-a/IFN-g, and in the presence or
absence of R2B2 antibodies. Purified normal rabbit IgG was used as
a control (R&D Systems). Samples were analysed using the Apotest-
FITC kit (DAKO, Glostrup, Denmark), in accordance with the
manufacturer’s instructions. Median percentage of apoptotic Jurkat
cells was detected. The data are the averages of three experiments.
Detection of EMAP-II by Western blotting
PAGE was used to separate proteins from DLD-1 and HT29 cell
extracts and supernatants from coculture experiments for 4 and
24h. EMAP-II was detected by Western blotting with the R2B2
polyclonal antibodies as described previously (Tas et al, 1997;
Murray et al, 2004). Antibody binding was revealed by enhanced
chemiluminescence.
Enzyme-linked-immuno-sorbent assay for soluble
EMAP-II
Detection of soluble EMAP-II was performed after incubating cells
in serum-free RPMI medium for four and 24h in normal and
hypoxic conditions in coculture experiments. Recombinant EMAP-
II was dissolved in RPMI medium to a final concentration of
50ngml
 1 for use as external standard. Samples were analysed
using human EMAP-II (Bio-Source International, Camarillo, CA,
USA).
Flow cytometric analysis of cell surface expression of
EMAP-II
DLD-1 and HT29 cells were incubated in RPMI medium for 24h in
normal and hypoxic conditions. Immunofluorescent detection
of EMAP-II was performed as described previously (Murray
et al, 2004). Staining was carried out on fixed, permeabilised
cell suspensions with R2B2 antibodies or purified IgG from
preimmune rabbit serum (R&D Systems) at 1mgml
 1 for 2h. The
secondary antibody was goat anti-rabbit FITC-conjugate (Sigma-
Aldrich). Additional cell samples were incubated with the
secondary FITC-conjugated antibody, but without primary anti-
body, as controls. Samples were analysed on a Becton Dickinson
FACScan using the LYSIS program.
Antibodies and recombinant proteins
EMAP-II was detected using the polyclonal rabbit antibody R2B2.
The characteristics of R2B2 have been described elsewhere (Tas
et al, 1997; Barnett et al, 2000; Murray et al, 2000). HRP- and FITC-
labelled anti-rabbit or anti-goat IgG antibodies (Sigma-Aldrich)
were used for detection of primary antibodies. Recombinant
Human carbonic anhydrase IX (CA IX) is a trans-membrane
glycoprotein, first sequenced and characterised as membranous
CA IX (MN/CA IX) by Opavsky et al (1996), and is recognised as a
surrogate marker of hypoxia in tumours (Beasley et al, 2001;
Wykof et al, 2001). Polyclonal anti-CA IX antibody antibody was
a gift from Bayer Pharma (Germany). Rabbit polyclonal anti-
body against active caspase-3 was obtained from R&D Systems
(Abingdon, UK). Cleaved Poly (ADP-ribose) Polymerase (PARP)
antibody was obtained from Cell Signaling (UK). Recombinant
human TNF-a and IFN-g were purchased from PeproTech
(London, UK).
Immunohistochemistry
Archival samples of colorectal cancers were analysed for EMAP-II,
CA IX, active caspase-3, and cleaved PARP expression. Slides were
dewaxed in Histolene (Cell Path Plc, Hemel Hempstead, UK),
before being rehydrated in graded ethanol solutions (100–30%).
Antigen retrieval was performed by boiling the slides for 10min in
citrate buffer (10mM citric acid, 25mM sodium hydroxide). Slides
were blocked with normal goat serum for 20min. EMAP-II and CA
IX were identified by incubating the slides with purified polyclonal
antibodies R2B2 (1mgml
 1 in PBS), M75 anti-human CA IX
antibody at a 1:250 dilution for 1h at room temperature,
respectively. Secondary detection was performed using the
Vectastain Elite kit, according to manufacturer’s instructions
(Vector Laboratories, Burlingame, CA, USA). Slides were counter-
stained with haematoxylin solution (Vector Laboratories), dehy-
drated in ethanol, and mounted with DePeX polystyrene solution
(BDH, Poole, UK).
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sApoptotic cell death was detected in TILs by immuno-
histochemistry using antibodies against active caspase-3 (R&D
Systems) and cleaved PARP antibody (Cell Signaling). After
deparaffinisation and rehydration, an antigen retrieval was
performed, as described above. Active caspase-3 was identified
by incubating the slides with rabbit polyclonal against active
caspase-3 (1:200 in TBS) for 1h at room temperature. Cleaved
PARP was detected by incubating the slides with cleaved PARP
antibody at a 1:50 dilution in TBS at 41C overnight. Secondary
detection was performed as described above.
By-eye evaluation of active caspase-3 and cleaved PARP
staining
Cells were identified as active caspase-3-positive if there was
cytoplasmic and perinuclear localisation of stain. Localisation of
stain was nuclear in cleaved PARP-positive cells. From five
randomly selected fields of each section, two independent
observers, blinded to the clinicopathological features of these
cancers, counted one thousand cells. According to the proportion
of positive cells, the degree of staining achieved with their
antibodies was graded as follows: negative ( ); þ, 1–25% of
cells positive; þþ, 26–50% of cells positive; þþþ, 51–75%
of cells positive; þþþþ, 76–100% of cells positive.
Image analysis
Quantitative data for EMAP-II and CA IX expression were
acquired with a semiautomatic method based on computerised
digital image analysis system (Gray Cancer Institute, UK), which
has been shown to be a reproducible method (Araya et al, 1998;
de Moissac et al, 2000). Analysis of the hypoxic marker and
EMAP-II was performed with  100 magnification. A contour line
was drawn to delineate the area of EMAP-II and CA IX expression
in the tumour area. Four different sections of each slide were
analysed for EMAP-II and CA IX staining; the parameters
measured were (1) tumour area in the field of view, (2) the
tumour area stained for each protein and (3) the stained area as a
percentage of the tumour area. The mean of these parameters was
used for each patient in the statistical analysis. Analysis settings
were reviewed and confirmed by Dr JC Murray.
Statistical analysis
Analysis of activity of caspase-3 and median percentage of
apoptotic cells was performed with Microsoft Excel (Redmond,
WA, USA). The data were expressed as mean7s.e.m. from three
independent experiments and the statistical significance was tested
by the Student’s test. Statistical analysis was performed using the
SPSS for Windows program package (Chicago, IL, USA). For
two variables measured on a continuous scale, the Spearman rank
correlation test was used to test the correlation. Multivariate
regression analysis was performed including different patho-
logical features. P-values p 0.05 were considered significant.
Analysis of ELISA data was performed with Microsoft Excel
(Redmond, WA, USA).
RESULTS
Apoptosis of tumour-infiltrating lymphocytes induced
by hypoxia in colon cancer
As a surrogate marker for detection of hypoxia, we examined
expression of CA IX in archival specimens of colorectal tissues by
immunohistochemistry. To evaluate apoptosis of TILs in hypoxic
regions, we detected the presence of apoptotic cells using active
caspase-3 and cleaved PARP. Figure 1A shows the typical pattern
of a section of colorectal carcinoma, with staining of CA IX. There
is a strong membranous and cytoplasmic staining within the
malignant epithelial cells. Weak staining of CA IX was observed in
16 carcinomas (22%), whereas 27 (37%) showed a moderate
positive reaction and 29 (41%) a strong reaction. The 11
adenomatous lesions were obtained from 11 patients. No staining
for CA IX was found in one lesion (10%) whereas seven lesions
showed weak staining (63%) and three (27%) a moderate reaction.
The pattern of apoptotic TILs was observed through areas of
hypoxic tumour. Figure 1B shows moderate reactivity to active
caspase-3 in TILs. Figure 1C shows immunohistochemical staining
of cleaved PARP antibody detecting the nuclear localisation of
cleaved PARP in TILs surrounding the colorectal tumour. One
apoptotic lymphocyte was detected in TILs in normal colon
(Supplementary Figure 1).
Relationship between CA IX, cleaved PARP, and caspase-3
expression and the clinicopathological features of
colorectal cancer
Increased levels of CA IX expression was significantly correlated
with presence of metastasis (P¼0.01); increasing Dukes’ stage
(Po0.01); lymphatic metastasis (P¼0.01); vascular metastasis
(P¼0.05); lymph node metastasis (P¼0.02); death (P¼0.03) and
recurrence (P¼0.02), but not with tumour size, site, differentia-
tion, gender or age of patients (P40.05) (Table 1). Patient and
tumour characteristics details are given in supplementary Table 1.
In comparison, cleaved PARP in TILs showed significant correla-
tion with lymphatic metastasis (P¼0.04) and increasing Dukes’
stage (P¼0.02), although not with other features (P40.05)
(Table 2). Caspase-3 expression in TILs showed significant
correlation with increasing Dukes’ stage (P¼0.02), but not with
other features (P40.05) (Supplementary Table 2).
Colorectal cancer cells express high levels of EMAP-II in
apoptotic regions
We examined expression of EMAP-II in archival specimens of
colorectal tissues by immunohistochemistry. Figure 1D shows a
moderately differentiated adenocarcinoma of the colon stained
with EMAP-II. There is strong cytoplasmic staining within the
malignant epithelial cells. Weak staining for EMAP-II was found in
seven carcinomas (10%), whereas 14 (20%) showed a moderate
positive reaction and 51 (70%) a strong reaction. Most adenoma-
tous lesions showed a weak or moderate staining for EMAP-II.
Relationship between EMAP-II expression and the
clinicopathological features of colorectal cancer
Increased levels of EMAP-II expression was significantly correlated
with presence of metastasis (P¼0.05); increasing Dukes’ stage
(Po0.01); presence of lymphatic metastasis (P¼0.05); vascular
metastasis (P¼0.01); lymph node metastasis (Po0.01); death
(P¼0.03) and development of recurrence (P¼0.01). No associations
with other clinicopathological features were found (P40.05) (Table 3).
Association between hypoxia, TILs apoptosis and EMAP-II
in colorectal cancer
Interestingly, our results showed CA IX expression in colorectal
cancer was positively associated with cleaved PARP expression in
TILs (P¼0.02), as well as with active caspase-3 expression in TILs
(P¼0.04). EMAP-II expression was also correlated with CA IX
expression in CRC patients (P¼0.03).
EMAP-II is released under hypoxic conditions in vitro
Our results suggest that hypoxia induces apoptosis of lymphocytes
through EMAP-II, to confirm that EMAP-II are expressed by
EMAP-II-dependent lymphocyte
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by western blotting, flow cytometry and ELISA for soluble EMAP-
II. Figure 2A demonstrates that mature EMAP-II protein was
detected in the supernatants of DLD-1 cells exposed to hypoxia for
Figure 1 Association between hypoxia, TILs apoptosis and EMAP-II in
CRC in vivo.( A) Immunohistochemical staining of a moderately
differentiated adenocarcinoma of the colon with polyclonal anti-CA IX
antibody. There is a strong membranous and cytoplasmic staining within
the malignant epithelial cells (original magnification  200). (B) TILs in
tumourous tissues were strongly reactive with antiactive caspase-3
antibody (original magnification  400). (C) Apoptotic TILs immunos-
tained against cleaved PARP antibody (original magnification  400). (D)
Strong brown cytoplasmic staining of malignant epithelial cells in the
tumour with EMAP-II (original magnification  200).
Table 1 Relationship between CA IX expression and clinico-pathological
features
Variables Total 1–25% 26–50% 51–75% 76–100% P-value
a
Age tertile NS
b
o61 20 6 5 6 3
61.1–71.9 22 7 8 3 4
X72 30 3 14 10 3
Type NS
Nonmucinous 66 15 23 18 10
Mucinous 6 1 4 1
Site NS
Left colon 3 1 1 1
Caecum 17 4 8 5
Right colon 4 1 1 1 1
Transverse, splenic 3 1 2
Rectum 24 5 8 8 3
Rectum-sigmoid 8 2 3 1 2
Sigmoid 13 4 5 3 1
Size median NS
oMedian 28 5 11 10 2
XMedian 44 11 16 9 8
Dukes’ stage o0.01
A1 8 1 0 3 4 1
B3 2 6 2 1 4 1
C 22 3 11 8
Differentiation 0.01
Moderate 4 1 1 1 1
Well 62 14 25 18 5
Poor 6 1 1 3 1
Metastasis 0.01
Primary 72 16 27 19 10
Secondary 13 2 5 4 2
Lymphatic metastasis 0.01
At DX
c 24 1 4 11 8
During FU
d 21 1
No metastasis 46 14 22 8 2
Vascular metastasis 0.05
oMedian 37 6 16 9 6
XMedian 35 10 11 10 4
Lymph node metastasis 0.02
No 43 14 20 8 1
Yes 29 2 7 11 9
Death 0.03
No 28 10 9 6 3
Yes 44 6 18 13 7
Recurrence 0.02
Yes 25 1 9 9 6
No 42 14 17 8 3
NA 5 1 1 2 1
Gender NS
Male 42 9 13 13 7
Female 30 7 14 6 3
aP-value by multivariate regression analysis.
bNot significant.
cAt Dukes’ C.
dNodal
recurrence.
EMAP-II-dependent lymphocyte
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sfour and 24h. Conditioned medium from HT29 cells contain
barely detectable levels of soluble EMAP-II in normal and hypoxic
conditions. The blots show a relative increase in Mr 34000 EMAP-
II in hypoxic cell lysates.
There was significant change in total EMAP-II antigen in
hypoxic cultures by ELISA (Figure 2B). Consistent with the
Western blotting data, exposure to hypoxia for 24h resulted in a
four-fold increase in release of EMAP-II by DLD-1. We observed
Table 2 Relationship between cleaved PARP in TILs and clinico-
pathological features
Variables Total 1–25% 26–50% 51–75% 76–100% P-value
a
Age tertile NS
b
o61 20 13 1 4 2
61.1–71.9 22 7 5 9 1
X72 30 9 8 12 1
Type NS
Nonmucinous 66 27 14 21 4
Mucinous 6 2 4
Site NS
Left colon 3 1 2
Caecum 17 5 4 6 2
Right colon 4 2 2
Transverse, splenic 3 2 1
Rectum 24 9 2 13
Rectum-sigmoid 8 4 2 2
Sigmoid 13 6 5 2
Size median NS
oMedian 28 10 7 9 2
XMedian 44 19 7 16 2
Dukes’ stage 0.02
A1 8 1 0 3 4 1
B3 2 1 2 1 0 9 1
C2 2 7 1 1 2 2
Differentiation NS
Moderate 4 2 1 1
Well 62 25 12 22 3
Poor 6 2 1 2 1
Metastasis NS
Primary 72 29 14 25 4
Secondary 13 1 4 6 2
Lymphatic metastasis 0.04
At DX
c 24 9 13 2
During FU
d 21 1
No metastasis 46 20 13 11 2
Vascular metastasis NS
oMedian 37 16 7 12 2
XMedian 35 13 7 13 2
Lymph node metastasis NS
No 43 16 5 13 9
Yes 29 13 9 2 5
Death NS
No 28 12 6 10
Yes 44 17 8 15 4
Recurrence NS
Yes 25 9 10 6
No 42 19 4 14 5
NA 5 1 4
Gender NS
Male 42 15 7 17 3
Female 30 14 7 8 1
aP-value by multivariate regression analysis.
bNot significant.
cAt Dukes’ C.
dNodal
recurrence.
Table 3 Relationship between EMAP-II expression and clinico-patholo-
gical features
Variables Total 1–25% 26–50% 51–75% 76–100% P-value
a
Age tertile NS
b
o61 20 3 2 4 11
61.1–71.9 22 1 6 5 10
X72 30 3 6 7 14
Type NS
Nonmucinous 66 7 13 15 31
Mucinous 6 1 1 4
Site NS
Left colon 3 2 1
Caecum 17 2 5 3 7
Right colon 4 4
Transverse, splenic 3 3
Rectum 24 3 3 6 12
Rectum-sigmoid 8 2 1 5
Sigmoid 13 2 4 6 1
Size median NS
oMedian 28 5 4 5 14
XMedian 44 2 10 12 20
Dukes’ stage o0.01
A1 8 2 4 3 9
B3 2 4 7 8 1 3
C2 2 1 3 5 1 3
Differentiation NS
Moderate 4 1 3
Well 62 6 12 15 29
Poor 6 2 1 3
Metastasis 0.05
Primary 72 7 14 16 35
Secondary 13 1 1 4 7
Lymphatic metastasis 0.05
At DX
c 24 1 4 6 13
During FU
d 22
No metastasis 46 6 10 8 22
Vascular metastasis 0.01
oMedian 37 5 6 9 17
XMedian 35 2 8 7 18
Lymph node metastasis o0.01
No 43 6 9 8 20
Yes 29 1 5 8 15
Death 0.03
No 28 3 5 8 12
Yes 44 4 9 8 23
Recurrence 0.01
Yes 25 1 5 7 12
No 42 6 9 7 20
NA 5 2 3
Gender NS
Male 42 3 10 7 22
Female 30 4 4 9 13
aP-value by multivariate regression analysis.
bNot significant.
cAt Dukes’ C.
dNodal
recurrence.
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ssignificant difference in EMAP-II expression between normal and
hypoxic cells at four and 24h. Conditioned media derived from the
cultures of HT29 cells showed barely detectable levels in normal
and hypoxic conditions (Supplementary Figure 2).
Cell surface expression of EMAP-II on colorectal cancer cell
lines was examined by flow cytometry using R2B2 polyclonal
antibodies (Figure 2C). Both DLD-1 and HT29 demonstrated
cell surface expression of EMAP-II, showing increases in mean
fluorescence over negative controls in the range of three- to four-
fold. The specificity of this staining was confirmed by the use
of a preimmune antibody control, which showed no membrane
staining in any of the cell lines. Hypoxia caused a further seven-
fold increase in mean fluorescence associated with R2B2 antibody
binding to HT29 cells. There is only two- to three-fold increase in
hypoxic DLD-1 cells.
Apoptosis of T-cells induced by hypoxia is
EMAP-II-dependent in vitro
The median percentage of apoptotic Jurkats cocultured with DLD-
1 for 24h in hypoxia is illustrated in Figure 3. Jurkats alone showed
low levels of apoptosis under hypoxic conditions (Figure 3Ai).
However, Jurkat cells displayed increased apoptosis when cultured
with hypoxic tumour cells (P¼0.03) (Figure 3Aii). Coculture
of Jurkats with cytokine-treated tumour cells in hypoxia caused
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Figure 2 Effect of hypoxia on EMAP-II expression in CRC in vitro.( A)
Western blot of extracts of DLD-1 (Lanes 1–4 and 9–12) and HT29 cells
(Lanes 5–8 and 13–16). Cells were grown in control or hypoxia for 4 and
24h. Lanes 1, 3, 5, 7, control cell lysates at 4, 24h; Lanes 9, 11, 13, 15
conditioned media from the same cells; Lanes 2, 4, 6, 8, lysate from hypoxic
cells for 4, 24h; Lanes 10, 12, 14, 16 conditioned media from hypoxic cells.
(B) ELISA of conditioned medium from DLD-1 for soluble EMAP-II. Cells
exposed to hypoxia for 4 and 24h. Data represent mean of three
determinations7s.d. (C) Flow cytometric determinations of cell surface
EMAP-II expression in hypoxia. Untreated DLD-1 and HT29 tumour cells
without primary antibody (dashed lines); untreated cells incubated with
preimmune antibodies (dotted lines); control cells incubated with R2B2
antibodies against EMAP-II (thin lines); hypoxic cells incubated with R2B2
antibodies against EMAP-II (thick black lines).
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Figure 3 Hypoxia induced apoptosis of TILs through EMAP-II in vitro.
Jurkat cells cocultured with tumour cells. FITC-labelled annexin-V assay (A)
and caspase-3 activity (B) were performed to determine the level of
apoptosis. (i) Jurkats alone; (ii) Jurkats cocultured with tumour cells; (iii)
Jurkats cocultured with cells pretreated with TNF-a/IFN-g; (iv) Jurkats
cocultured with cells pretreated with TNF-a/IFN-g in the presence of R2B2
blocking antibodies; (v) Jurkats cocultured with cells pretreated with TNF-a/
IFN-g in the presence of control IgG. The data shown are the averages of
three experiments. The data shown are the averages of three experiments
(mean7s.e.m.). ** Indicates significance at Po0.05 in comparison to
controls. (C) Concentration-dependent increase in caspase-3 activity in
jurkats with decreasing concentrations of anti-EMAP-II antibody. Data are
means; error bars represent s.e.m. (D) Caspase-3 activity in Jurkats over
time. 1, JurkatsþHT29 pretreated with TNF-a/IFN-g in normoxia; 2,
JurkatsþHT29 pretreated with TNF-a/IFN-g in hypoxia; 3, JurkatsþHT29
pretreated with TNF-a/IFN-g and R2B2 antibodies in normoxia; 4,
JurkatsþHT29 pretreated with TNF-a/IFN-g and R2B2 antibodies in
hypoxia. Data are presented as the mean7s.e.m. of at least three separate
experiments.
EMAP-II-dependent lymphocyte
MMS Youssef et al
740
British Journal of Cancer (2006) 95(6), 735–743 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sa significant increase in apoptosis in comparison to control
(Po0.05) (Figure 3Aiii). To determine whether EMAP-II is indeed
responsible for apoptosis of T-cells induced by hypoxia in CRC, we
performed blocking experiments using R2B2 antibodies or purified
normal rabbit IgG as a control. Blocking experiments using the
anti-EMAP-II antibody in the coculture caused a marked reduction
in the percentage of apoptotic Jurkat cells in hypoxia (Figure 3Aiv).
Control IgG had no effect on hypoxia-induced lymphocyte
apoptosis in cocultures (Figure 3Av). For HT29 cells, we have
the same data (supplementary Figure 3). Flow cytometric analysis
of apoptosis in Jurkat cells are given in supplementary Figure 3.
Caspase-3 activity was assayed in extracts of control Jurkats and
Jurkats cocultured under a variety of conditions with tumour cells
(Figure 3B). Jurkats cultured alone showed low levels of apoptosis
in hypoxia. Coculture of Jurkats with HT29 cells for 4h caused a
significant increase in the activity of caspase-3 in hypoxia.
Coculture with HT29 cells pretreated with TNF-a/IFN-g induced
a significant increase in caspase-3 activity in hypoxia (Po0.05).
Addition of R2B2-blocking antibodies against EMAP-II to the
coculture completely inhibited the generation of caspase-3 activity
in Jurkat cells in hypoxia. Control IgG had no effect caspase-3
activity in these experiments.
Blocking effect of anti-EMAP-II antibody is concentration-
dependent (Figure 3C). There was an increase in caspase-3 activity
with decreasing concentrations of anti-EMAP-II antibody. Con-
centration of 10mgml
 1 completely inhibited caspase-3 activity.
No effect was observed with the control one.
A significant increase in the activity of caspase-3 was observed
with increasing time in hypoxia (Figure 3D). The marked increase
in caspase-3-like activity may reflect an increase in the proportion
of cells undergoing apoptosis in hypoxia.
EMAP-II-induced lymphocyte apoptosis requires
cell–cell contact
To examine whether EMAP-II-induced lymphocyte apoptosis
was mediated by direct cell–cell contact (Figure 4), apoptosis of
TILs was analysed by separating the colorectal cancer cell lines
and Jurkats as a model for T lymphocytes through a 5mm filter
(Figure 4A). Contact coculture of Jurkats for 4h with tumour cells
either untreated or treated with TNF-a/IFN-g caused a significant
increase in caspase-3 activity compared to noncontact coculture
(Po0.05) (Figure 4B). Addition of R2B2 blocking antibodies
against EMAP-II to the contact coculture inhibited the activity of
caspase-3. Thus, prevention of cell–cell contact reduced lympho-
cyte apoptosis, indicating that direct cell–cell contact is required
for hypoxia-induced lymphocyte apoptosis.
DISCUSSION
It is well known that hypoxia can lead to cellular injury and
death, both through induction of apoptosis and via necrotic
cell death (Chae et al, 2001). In the present study, we provide
novel evidence for the participation of hypoxia in protecting
tumours against the immune system, by showing that hypoxia
can lead to death of tumour-infiltrating lymphocytes via an EMAP-
II-dependent mechanism.
TILs have been shown to be capable of specifically eliminating
tumour cells (Aebersold et al, 1991), but also to be rendered
potentially nonfunctional due to tumour-induced immunosup-
pression (Finke et al, 1990). In a previous study, we hypothesised
that EMAP-II might act in such an immunosuppressive role, by
directly inducing apoptosis in mitogen-activated lymphocytes
(Murray et al, 2004).
In this paper, we have used a number of techniques to
demonstrate a possible link between EMAP-II expression, hypoxia
(which we previously showed to enhance EMAP-II expression),
and lymphocyte apoptosis in vivo and in vitro. Our data show
that hypoxia is spatially associated with apoptosis in TILs in
CRC. In vivo, we observed that hypoxic regions contain signi-
ficant numbers of TILs demonstrating the presence of active
caspase-3 and proteolytic cleavage of PARP. As caspase-3 is a
critical mediator of apoptosis (Slee et al, 1999), it may be a
potential marker for predicting apoptosis in TILs in colorectal
cancer. Activation of caspase-3 has been linked to the proteolytic
cleavage of cellular substrates including PARP (Nicholson and
Thornberry, 1991).
In a previous study, we have shown that low oxygen levels can
enhance EMAP-II release and conversion (Barnett et al, 2000).
Hypoxia is known to upregulate the expression and release of
matrix metalloproteinases and plasminogen activator-1 from
tumour cells (Koong et al, 2000; Canning et al, 2001), and these
enzymes could potentially be involved in EMAP-II processing at
the cell surface. In this article, we could demonstrate in vitro that
hypoxia leads to the cleavage of proEMAP-II and the subsequent
release of mature EMAP-II protein from DLD-1 cells. However,
barely detectable mature EMAP-II was detected in supernatants
derived from hypoxic HT29 cells. This is consistent with previous
publication (Murray et al, 2004). With this study, we are the first to
analyse surface expression of EMAP-II in hypoxia. Analysis of
EMAP-II surface expression in HT29 cells revealed significant
difference between hypoxic and normal cells. We observed
increase in EMAP-II surface expression in hypoxic DLD-1 cells.
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Figure 4 EMAP-II-Induced apoptosis of lymphocytes requires cell–cell
contact. (A) Experimental design. Tumour cells and Jurkats were
cocultured in contact and noncontact conditions. In the noncontact
cocultures, tumour cells were plated at the bottom of a culture-plate well
and Jurkats at the bottom of a culture insert. The culture insert was placed
in the well and the cells were then incubated. In the contact cocultures,
tumour cells and Jurkats were plated at the bottom of the same culture-
plate well. (B)A¼Jurkats were cultured with tumour cells, B¼Jurkatsþ
tumour cells pretreated with TNF-a/IFN-g,C ¼Jurkatsþtumour cells
pretreated with TNF-a/IFN-g and R2B2. Results represent the mean of
three determinations7s.e.m. * Indicates significant deviations from control
values, Po0.05.
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strong association between EMAP-II, active caspase-3, and cleaved
PARP in TILs within tumours. Furthermore our study confirms
an association between expression of EMAP-II and that of CA IX,
a surrogate marker of hypoxia, in colorectal tissues. These
findings are supported by the in vitro studies, which show that
hypoxia alone induces only a small change in levels of apoptosis in
Jurkat cells. However, increased levels of apoptosis were seen
when colorectal cancer cells were cocultured with Jurkat cells
in normoxia, and even higher levels in hypoxic cocultures.
Pretreatment of colorectal cancer cells with cytokines again
produced increased apoptosis of Jurkat cells in hypoxia. By
preincubating tumour cells with blocking antibody, this phenom-
enon was demonstrated to be EMAP-II-dependent.
We also showed previously that EMAP-II treatment leads to
activation of caspase-8 in lymphocytes, implicating a death
receptor pathway (Murray et al, 2004). Data in the present study
present further evidence in support of this hypothesis, in the form
of caspase-3 activation and PARP cleavage. However, while it is
clear that a caspase cascade probably plays a role, the nature of the
death receptor is not clear.
In the in vitro studies, caspase-3 activity was low in normoxic
noncontact cocultures, although Jurkat apoptosis was increased in
these conditions compared to single cell type cultures, suggesting
that more than one mechanism may be responsible for Jurkat cell
death in this model. Levels of caspase-3 rose significantly in
hypoxic conditions, a phenomenon which has been reported by
others (Todor et al, 2002; Parikh et al, 2003). In our experiments,
active caspase-3 was observed in Jurkat cells cocultured with HT29
pretreated with TNF-a/IFN-g within 4h of hypoxia treatment, with
increasing activity over time in hypoxia. While cytokine pretreat-
ment of tumour cells increased Jurkat cell death, the effect was
always enhanced in hypoxic conditions. These data suggest that
hypoxia plays an important role in the viability of lymphocytes
within the tumour microenvironment.
Previous studies have shown that EMAP-II can induce apoptosis
either through direct cell–cell contact, or by acting as a soluble
mediator signalling cell death (Murray et al, 2004). Our current
data, for both tumour cell lines, suggest that direct cell–cell
contact is a more potent mechanism for induction of lymphocyte
apoptosis in hypoxia. While there may be other mechanisms
contributing to cell killing when there is contact, the equivalent
effect of antibody blocking in contact and noncontact cultures
suggest that the EMAP-II mechanism predominates.
In summary, we have reported that in colorectal cancer hypoxia
stimulates apoptosis in TILs via an EMAP-II-dependent mechan-
ism. It is well established that poor oxygenation of solid tumours is
associated with poor prognosis, and it has been suggested that this
may have less to do with direct effects of hypoxia on the efficacy of
treatment modalities, and more to do with the development of
resistant tumour cell clones under hypoxic conditions (Weinmann
et al, 2004). Our study suggests that hypoxia induces apoptosis in
TILs via an EMAP-II-dependent mechanism. This may represent
yet another means by which the presence of hypoxia confers a
growth advantage on tumour cells.
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